Press

Press Releases

To Fight Cramps, Christoph Westphal Taps Boston All-Stars for $40M
Read More

Flex Pharma Raises $40 Million — Top Tier Syndicate Supports Novel Treatments for Neuromuscular Disorders
Read More

Executive Profile: Arthur Tzianabos of OvaScience
Read More

Christoph Westphal Globe Article on Boston’s Prominence in Medicine, Music isn’t an Accident
Read More

Christoph Westphal Globe Article on the Biotech Industry and a Cure for Hepatitis C
Read More

Christoph Westphal Globe Article on Boston, Hub of the Pharma Universe
Read More

Flex Pharma Forms Distinguished Scientific Advisory Board
Read More

European Medicines Agency Recommends First-in-Class Medicine for Treatment of Duchenne Muscular Dystrophy
Read More

Longwood Portfolio Company Verastem in Bloomberg’s New Cancer Drug Targets Article
Read More

Christoph Westphal Globe Article on the Biotech Industry and a Cure for Hepatitis C
Read More

OvaScience Co-Founder David Sinclair, Ph.D., Selected by TIME as one of the 100 Most Influential People in The World
Read More

OvaScience Prices $50 Million Public Offering of Common Stock
Read More

Calithera Biosciences Initiates Three Phase 1 Trials with First-in-Class Glutaminase Inhibitor CB-839 in Patients with Advanced Solid and Hematological Cancers
Read More

Christoph Westphal Globe Article on Boston's Blooming Biotech Ecosystem
Read More

PTC’s Joint Program In Spinal Muscular Atrophy Enters First Stage Of Clinical Development
Read More

Verastem Announces Addition to the NASDAQ Biotechnology Index
Read More

OvaScience and Intrexon Collaborate to Accelerate Development of OvaScience's OvaTureSM Technology for Infertility Treatments
Read More

Astellas Pharma Inc. Announces R&D Collaboration and Exclusive Right to Acquire an Option to Purchase Longwood Portfolio Company Mitokyne in Q2 2013 Financial Results Call
Read More

Calithera Biosciences Secures $35 Million in Series D Financing
Read More

Astellas and Mitokyne to Pursue Mitochondria-Related Disease Therapies
Read More

Verastem Featured in Cover Article on Biotech Startups in Germany’s Largest Business Newspaper, Handelsblatt
Read More

Verastem Initiates Trial of Defactinib in Japan
Read More

Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in
Patients with Mesothelioma

Read More

PTC Therapeutics Announces Achievement of Major Milestone in SMA Collaboration
Read More

Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib
in Mesothelioma

Read More

Verastem’s Defactinib in Combination with Weekly Paclitaxel Achieves a Complete Response in Platinum-Resistant Ovarian Cancer
Read More

OvaScience co-founder Dr. Jonathon Tilly, Ph.D., selected by the Boston Business Journal as a 2013 Champion in Healthcare
Read More

Verastem Announces Pricing of Public Offering of Common Stock
Read More

OvaScience on NECN CEO Corner
Read More

Christoph Westphal in NY Times Article on Biotech Company Surge
Read More

Verastem Successfully Completes Phase 1 Stage of VS-6063 and Paclitaxel
Combination Trial

Read More

PTC Therapeutics Prices Initial Public Offering
Read More

Oh, Baby: OvaScience’s Roadmap to Next-Generation IVF
Read More

Verastem Drug Wins Orphan Status in EU
Read More

OvaScience on CNBC Fast Money
Read More

OvaScience Chief Executive Officer Selected Entrepreneur of The Year 2013 Finalist for New England by Ernst & Young
Read More

Cambridge Fertility Firm OvaScience Hopes NASDAQ Move Will Expand Investor Base
Read More

IlluminOss Medical Names Dirk Kuyper as Chief Executive Officer
Read More

OvaScience Announces Agreement for $35 Million Private Placement
Read More

PTC Therapeutics Closes $60 Million Private Financing
Read More

Verastem Launches Ovarian Cancer Trial
Read More

VS-6063 Article by Mesothelioma Advocacy Group
Read More

Verastem Reports Data on Focal Adhesion Kinase Program at the 2012 EORTC Symposium on Molecular Targets and Cancer Therapeutics
Read More

Dr. Michelle Dipp - Women in Biotech 2012
Read More

At 36, OvaScience’s Top Executive Reflects Biotech’s Next Generation
Read More

Verastem to Host NASDAQ Opening in its Cambridge Laboratory May 22, 2012
Read More
Download Article in PDF 

OvaScience Secures $37 Million in Series B Financing
Read More

Verastem, Inc. Announces Pricing of Initial Public Offering
Read More
Download Article in PDF 

OvaScience’s Approach to Fertility to be Highlighted at ASRM
Read More

Longwood Launches First Fund
Read More

Verastem Secures $16 Million in Series A Financing for Novel Cancer Stem Cell Drugs
Read More

Lilly to Acquire Alnara Pharmaceuticals
Read More

 

News Reports

Verastem Launches Ovarian Cancer Trial
Boston Business Journal: February 5, 2013
Read More

Scientists Target Tumors’ Most Resilient Cells
By: Ron Winslow | Wall Street Journal: December 21, 2010
Read More

Focus Turns to Cancer Stem Cells
By: Karen Weintraub | The Boston Globe: December 1, 2010
Read More

Screening Could Lead to More Potent Cancer Drugs
By: Nicholas Wade | The New York Times: August 13, 2009
Read More